Karine Flem Karlsen, PhD
Postdoctoral Associate - Bosenberg Lab
Research & Publications
Biography
News
Coauthors
Selected Publications
- A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma.Pozniak J, Pedri D, Landeloos E, Van Herck Y, Antoranz A, Vanwynsberghe L, Nowosad A, Roda N, Makhzami S, Bervoets G, Maciel LF, Pulido-Vicuña CA, Pollaris L, Seurinck R, Zhao F, Flem-Karlsen K, Damsky W, Chen L, Karagianni D, Cinque S, Kint S, Vandereyken K, Rombaut B, Voet T, Vernaillen F, Annaert W, Lambrechts D, Boecxstaens V, Saeys Y, van den Oord J, Bosisio F, Karras P, Shain AH, Bosenberg M, Leucci E, Paschen A, Rambow F, Bechter O, Marine JC. A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma. Cell 2024, 187: 166-183.e25. PMID: 38181739, DOI: 10.1016/j.cell.2023.11.037.
- A pan-SARS-CoV-2-specific soluble angiotensin-converting enzyme 2-albumin fusion engineered for enhanced plasma half-life and needle-free mucosal delivery.Benjakul S, Anthi AK, Kolderup A, Vaysburd M, Lode HE, Mallery D, Fossum E, Vikse EL, Albecka A, Ianevski A, Kainov D, Karlsen KF, Sakya SA, Nyquist-Andersen M, Gjølberg TT, Moe MC, Bjørås M, Sandlie I, James LC, Andersen JT. A pan-SARS-CoV-2-specific soluble angiotensin-converting enzyme 2-albumin fusion engineered for enhanced plasma half-life and needle-free mucosal delivery. PNAS Nexus 2023, 2: pgad403. PMID: 38077689, DOI: 10.1093/pnasnexus/pgad403.
- IL-7R licenses a population of epigenetically poised memory CD8+ T cells with superior antitumor efficacy that are critical for melanoma memoryMicevic G, Daniels A, Flem-Karlsen K, Park K, Talty R, McGeary M, Mirza H, Blackburn H, Sefik E, Cheung J, Hornick N, Aizenbud L, Joshi N, Kluger H, Iwasaki A, Bosenberg M, Flavell R. IL-7R licenses a population of epigenetically poised memory CD8+ T cells with superior antitumor efficacy that are critical for melanoma memory. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2304319120. PMID: 37459511, PMCID: PMC10372654, DOI: 10.1073/pnas.2304319120.
- Heterogeneous Expression and Subcellular Localization of Pyruvate Dehydrogenase Complex in Prostate Cancer.Nunes-Xavier CE, Mingo J, Emaldi M, Flem-Karlsen K, Mælandsmo GM, Fodstad Ø, Llarena R, López JI, Pulido R. Heterogeneous Expression and Subcellular Localization of Pyruvate Dehydrogenase Complex in Prostate Cancer. Front Oncol 2022, 12: 873516. PMID: 35692804, DOI: 10.3389/fonc.2022.873516.
- Antibody variable sequences have a pronounced effect on cellular transport and plasma half-life.Grevys A, Frick R, Mester S, Flem-Karlsen K, Nilsen J, Foss S, Sand KMK, Emrich T, Fischer JAA, Greiff V, Sandlie I, Schlothauer T, Andersen JT. Antibody variable sequences have a pronounced effect on cellular transport and plasma half-life. IScience 2022, 25: 103746. PMID: 35118359, DOI: 10.1016/j.isci.2022.103746.
- Progress and challenges for the machine learning-based design of fit-for-purpose monoclonal antibodies.Akbar R, Bashour H, Rawat P, Robert PA, Smorodina E, Cotet TS, Flem-Karlsen K, Frank R, Mehta BB, Vu MH, Zengin T, Gutierrez-Marcos J, Lund-Johansen F, Andersen JT, Greiff V. Progress and challenges for the machine learning-based design of fit-for-purpose monoclonal antibodies. MAbs 2022, 14: 2008790. PMID: 35293269, DOI: 10.1080/19420862.2021.2008790.
- Targeting AXL and the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Melanoma.Flem-Karlsen K, McFadden E, Omar N, Haugen MH, Øy GF, Ryder T, Gullestad HP, Hermann R, Mælandsmo GM, Flørenes VA. Targeting AXL and the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Melanoma. Mol Cancer Ther 2020, 19: 895-905. PMID: 31871265, DOI: 10.1158/1535-7163.MCT-19-0290.
- Soluble AXL as a marker of disease progression and survival in melanoma.Flem-Karlsen K, Nyakas M, Farstad IN, McFadden E, Wernhoff P, Jacobsen KD, Flørenes VA, Mælandsmo GM. Soluble AXL as a marker of disease progression and survival in melanoma. PLoS One 2020, 15: e0227187. PMID: 31917795, DOI: 10.1371/journal.pone.0227187.
- B7-H3 Immune Checkpoint Protein in Human Cancer.Flem-Karlsen K, Fodstad Ø, Nunes-Xavier CE. B7-H3 Immune Checkpoint Protein in Human Cancer. Curr Med Chem 2020, 27: 4062-4086. PMID: 31099317, DOI: 10.2174/0929867326666190517115515.
- A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases.Flørenes VA, Flem-Karlsen K, McFadden E, Bergheim IR, Nygaard V, Nygård V, Farstad IN, Øy GF, Emilsen E, Giller-Fleten K, Ree AH, Flatmark K, Gullestad HP, Hermann R, Ryder T, Wernhoff P, Mælandsmo GM. A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases. Transl Oncol 2019, 12: 951-958. PMID: 31096111, DOI: 10.1016/j.tranon.2019.04.001.
- p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance.Flem-Karlsen K, Tekle C, Øyjord T, Flørenes VA, Mælandsmo GM, Fodstad Ø, Nunes-Xavier CE. p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance. Sci Rep 2019, 9: 5839. PMID: 30967582, DOI: 10.1038/s41598-019-42303-w.
- Soluble AXL is ubiquitously present in malignant serous effusions.Flem Karlsen K, McFadden E, Flørenes VA, Davidson B. Soluble AXL is ubiquitously present in malignant serous effusions. Gynecol Oncol 2019, 152: 408-415. PMID: 30448261, DOI: 10.1016/j.ygyno.2018.11.012.
- B7-H3 in Cancer - Beyond Immune Regulation.Flem-Karlsen K, Fodstad Ø, Tan M, Nunes-Xavier CE. B7-H3 in Cancer - Beyond Immune Regulation. Trends Cancer 2018, 4: 401-404. PMID: 29860983, DOI: 10.1016/j.trecan.2018.03.010.
- Immunoregulatory protein B7-H3 promotes growth and decreases sensitivity to therapy in metastatic melanoma cells.Flem-Karlsen K, Tekle C, Andersson Y, Flatmark K, Fodstad Ø, Nunes-Xavier CE. Immunoregulatory protein B7-H3 promotes growth and decreases sensitivity to therapy in metastatic melanoma cells. Pigment Cell Melanoma Res 2017, 30: 467-476. PMID: 28513992, DOI: 10.1111/pcmr.12599.
- Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors.Nunes-Xavier CE, Karlsen KF, Tekle C, Pedersen C, Øyjord T, Hongisto V, Nesland JM, Tan M, Sahlberg KK, Fodstad Ø. Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors. Oncotarget 2016, 7: 6891-901. PMID: 26771843, DOI: 10.18632/oncotarget.6902.